Eisai Co. Ltd.
www.eisai.com
Latest From Eisai Co. Ltd.
Court Restrains Dr Reddy’s In Indian Belviq Case
An Indian court has granted an interim injunction against Dr Reddy’s in a case concerning the alleged infringement of Eisai’s patent on Belviq. Dr Reddy’s, however, claims that Eisai is a “patent squatter” and expects to appeal against the order.
Polyphor's Stock Slides As Murepavadin Trials Are Halted
The Switzerland-headquartered group has suffered a setback as a couple of Phase III trials of its lead antibiotic were stopped temporarily after an unexpectedly high number of patients reported kidney injury.
Eisai's New Venture Fund Looks To ‘Excavate’ Innovation
Japanese pharma firm’s new venture capital fund aims to support and gain access to external innovation both at home and in the US, while a new alliance with a Japanese tech services firm will pursue opportunities in digital health and dementia.
Calm Before The Storm: Pharma Opens 2019 With A Bang In China
Products old, new and reimbursed were the driving force for foreign drug firms including AstraZeneca, Merck and Pfizer and Sanofi to smash growth in China in the first quarter.
Company Information
- Industry
-
Pharmaceuticals
- OTC, Consumer
- Therapeutic Areas
- Cancer
- Cardiovascular
- Gastrointestinal
- Gynecological, Urological
- Immune Disorders
- Infectious & Viral Diseases
- Inflammation
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
Asia
-
Pacific Rim
-
Japan
-
Japan
-
Pacific Rim
-
Asia
- Company Type
- Top Japanese Pharma
- Parent & Subsidiaries
- Eisai Co. Ltd.
- Senior Management
-
Haruo Naito, Pres. & CEO
Ryohei Yanagi, CFO
Edward Stewart Geary, CMO - Contact Info
-
Eisai Co. Ltd.
Phone: (81) 3 3817 3700
4-6-10 Koishikawa
Bunkyo-ku
Tokyo, 112-8088
Japan
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice